NFSG
TOVX icon

Newbridge Financial Services Group’s Theriva Biologics TOVX Stock Holding History

Newbridge Financial Services Group’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1 Hold
5
– – ﹤0.01% 1179
2025
Q4 		$1 Buy
+5
New +$1 ﹤0.01% 1175

Other funds holding TOVX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Newbridge Financial Services Group's TOVX Position: Q1 2026 in Review

Newbridge Financial Services Group held its Theriva Biologics (TOVX) position steady in Q1 2026 at 5 shares worth $1. The position accounts for ﹤0.01% of the portfolio, ranked #1179.

Newbridge Financial Services Group first reported a position in TOVX in Q4 2025 and has held it in 2 quarters since. 22 funds tracked by Wall St. Rank hold TOVX as of Q1 2026.

  • Newbridge Financial Services Group held 5 shares of Theriva Biologics worth $1 as of Q1 2026.
  • Newbridge Financial Services Group left its Theriva Biologics share count unchanged in Q1 2026.
  • Theriva Biologics made up ﹤0.01% of Newbridge Financial Services Group's portfolio in Q1 2026, its #1179 holding.
  • Newbridge Financial Services Group first reported a position in Theriva Biologics in Q4 2025 and has held it in 2 quarters since.
  • 22 funds tracked by Wall St. Rank held Theriva Biologics as of Q1 2026.

Based on Newbridge Financial Services Group's 13F filing for Q1 2026, filed 5 May 2026.